Springer Nature
Browse
13148_2019_681_MOESM5_ESM.docx (12.94 kB)

Additional file 5: of Combination treatment strategy for pancreatic cancer involving the novel HDAC inhibitor MPT0E028 with a MEK inhibitor beyond K-Ras status

Download (12.94 kB)
journal contribution
posted on 2019-05-29, 05:00 authored by Min-Wu Chao, Li-Hsun Chang, Huang-Ju Tu, Chao-Di Chang, Mei-Jung Lai, Yi-Ying Chen, Jing-Ping Liou, Che-Ming Teng, Shiow-Lin Pan
Table S1. IC50 of MPT0E028 and SAHA in pancreatic cell lines. AsPC-1, PANC-1, and BxPC-3 cells were treated with different concentrations of MPT0E028 or SAHA for 72 h. IC50 (the half maximal inhibitory concentration) was determined by MTT assay. (DOCX 12 kb)

Funding

Ministry of Science and Technology of Taiwan

History

Usage metrics

    Clinical Epigenetics

    Categories

    Keywords

    Pancreatic cancerMPT0E028MEK inhibitorEGFRK-Ras status

    Licence

    CC BY + CC0

    Exports

    RefWorks
    BibTeX
    Ref. manager
    Endnote
    DataCite
    NLM
    DC